Peregrine Pharmaceuticals, Inc. (NASDAQ-PPHM) is a biopharmaceutical company developing and manufacturing innovative monoclonal antibodies for the treatment of cancer and serious viral infections.
Thorpe Aug 7-11
...........................................................
International Meeting on Cellular Biology of Pathogens
When
07 - 10 Aug-11
Where
Sofitel, Sao Paulo, Brazil
Categories
Medical & Pharmaceutical
Conference Description:
International Meeting on Cellular Biology of Pathogen would provide an abundant opportunity to the biochemists, structural biologists, cell biologists, physiologists, scientists and geneticists to interact with experts and share their innovative ideas and thoughts get the positive solutions which would be benefited for the industry. International Meeting on Cellular Biology of Pathogen would have speakers such as Dominique Soldati Favre, University of Geneva, Elizabetta Ullu, Yale University Scholl of MedicineJoão Luiz M. Wanderley, INCA, Jorge Galan, Yale University Scholl of Medicine, Maria Cristina Pessolani, Instituto Oswaldo Cruz, Michael Duszenko, University of Tuebingen, Nicolas Fasel, Université de Lausanne, Philip Thorpe, UT, Southwestern Medical Center, Robert Menard, Institute Pasteur etc
biztradeshows.com
2011 Antibody Engineering and Antibody Therapeutics
Dec. 4-8
San Diego CA
Antibody Therapeutics - Wednesday, December 7, 2011
Session III: Next Generation Anti-Angiogenics
8:05
Chairperson's Opening Remarks
Philip E. Thorpe, Ph.D., Professor of Pharmacology and The Serena S. Simmons Distinguished Chair, University of Texas Southwestern
10:30
Targeting Tumor Vasculature and Reactivating Tumor Immunity with Bavituximab: Preclinical and Clinical Studies
Bavituximab is a therapeutic monoclonal antibody that is in randomized clinical trials in lung cancer and pancreatic cancer patients. It targets the immunosuppressive lipid, phosphatidylserine, which becomes exposed on tumor blood vessels and tumor cells. Bavituximab causes MDSCs to differentiate into tumoricidal M1 macrophages that destroy the tumor vasculature and tumor cells by ADCC. It also causes immature dendritic cells in tumors to mature and present tumor antigens, resulting in the generation of tumor-specific cytotoxic T-cells.
Philip E. Thorpe, Ph.D., Professor of Pharmacology and The Serena S. Simmons Distinguished Chair, University of Texas Southwestern
11:00
Identification of Pathways Involved in Resistance to Antibody Mediated Inhibition of VEGF in Murine Models of Cancer
Neutralizing antibodies to VEGF-A augment the activity of standard therapy in multiple tumor types. However, the variability in the response of different tumors to anti-VEGF therapy suggests that the mechanism of anti-VEGF action is complex and that resistance commonly develops. We have evaluated the response of 12 NSCLC xenografts to the anti-VEGF mAbs, bevacizumab and r84 (AT001), and have identified responder and non-responder cell lines. The biology has been interrogated through mRNA and protein profiling techniques linking particular genes/proteins to the resistance phenotype.
Rolf A. Brekken, Ph.D., Associate Professor of Surgery & Pharmacology, University of Texas Southwestern Medical Centerhttp://www.ibclifesciences.com/antibodyeng/agenda-ther.xml#main1
A new national initiative involving where volunteers can be matched to a scientific research project, or clinical trial, for which they might qualify.
Interested adult volunteers, parents or caregivers register on the ResearchMatch Web site (www.researchmatch.org) and indicate their interest in participating in research studies. Both healthy volunteers and those with specific medical conditions can sign up.
Message 26090452
CRISP has a new site for checking on grants.
projectreporter.nih.gov
Government link for definions used in trials.
prsinfo.clinicaltrials.gov
Patent office definitions:
uspto.gov |
